Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048154 | 0.89 | BCHE (0.43) | MEN1KMT2A | |
| SCHEMBL4037688 | 0.89 | KDM4E (0.46) | ADRB3ADRB1ADRB2MEN1KMT2A | |
| SCHEMBL4042381 | 0.82 | ADRB2 (0.59) | ADRB3ADRB1ADRB2MEN1KMT2A | |
| SCHEMBL4044458 | 0.81 | ADRB2 (0.39) | ADRB3ADRB1ADRB2MEN1KMT2A | |
| SCHEMBL3355569 | 0.78 | BACE1 (0.42) | MEN1KMT2A | |
| SCHEMBL4045258 | 0.77 | NR3C2 (0.41) | ADRB3ADRB1ADRB2KDM4E | |
| SCHEMBL7591136 | 0.76 | KMT2A (0.42) | MEN1KMT2A | |
| SCHEMBL4045744 | 0.74 | LMNA (0.41) | ADRB2KDM4ETDP1 | |
| SCHEMBL4044662 | 0.74 | ABCB1 (0.39) | ADRB3ADRB1ADRB2MEN1KMT2A | |
| SCHEMBL4047020 | 0.72 | SLC1A5 (0.49) | ACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | ADRB3 2130/4885ADRB1 1336/4885ADRB2 2258/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | ADRB3 1437/4885ADRB1 2069/4885ADRB2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.